


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-67. (Canceled)

68. (Currently amended) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;


R³ is -CH₂CONH₂;

R⁴ is NH₂;

R⁵ is methyl

(SEQ ID NO: 44).

69. (Currently amended) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;

R³ is -CH₂CONH₂;


R⁴ is NH₂;

R⁵ is acetyl

(SEQ ID NO: 45).

70-71. (Canceled)

72. (Currently amended) A pharmaceutical composition comprising a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;

R³ is -CH₂CONH₂;


R⁴ is NH₂;

R⁵ is methyl

(SEQ ID NO: 44);

and a pharmaceutically acceptable vehicle.

73. (Currently amended) A pharmaceutical composition comprising a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;

R³ is -CH₂CONH₂;


R⁴ is NH₂;

R⁵ is acetyl

(SEQ ID NO: 45);

and a pharmaceutically acceptable vehicle.

74. (Currently amended) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;


R³ is -CH₂CONH₂;

R⁴ is NH₂;

R⁵ is methyl

(SEQ ID NO: 44).

75. (Currently amended) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;

R³ is -CH₂CONH₂;


R⁴ is NH₂;

R⁵ is acetyl

(SEQ ID NO: 45).

76. (Currently amended) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a pharmaceutical composition comprising

a) a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;

R³ is -CH₂CONH₂;

R⁴ is NH₂;


R⁵ is methyl

(SEQ ID NO: 44); and

b) a pharmaceutically acceptable vehicle.

77. (Currently amended) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a pharmaceutical composition comprising

a) a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;

R³ is -CH₂CONH₂;

R⁴ is NH₂;

R⁵ is acetyl

(SEQ ID NO: 45); and

b) a pharmaceutically acceptable vehicle.

78. (Previously presented) The method of any one of claims 74-77 wherein the patient is a human.